: Amgen to continue to seek full approval of Lumakras cancer drug after FDA panel votes against it
Amgen will continue to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer.
Amgen will continue to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer.